SCHEMBL9900619

SCHEMBL9900619

Nc1ccc(Oc2[c]cccn2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
APAF1 O14727 1/20 0.56
ALDH1A1 P00352 6/20 0.45
TDP1 Q9NUW8 3/20 0.45
TSHR P16473 2/20 0.45
CYP3A4 P08684 1/20 0.45
MAOA P21397 3/20 0.44
MAPT P10636 5/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
GAA P10253 2/20 0.41
MITF O75030 1/20 0.41
GFER P55789 1/20 0.41
NLRP1 Q9C000 1/20 0.41
NOD2 Q9HC29 1/20 0.41
MAOB P27338 2/20 0.38
TEAD4 Q15561 1/20 0.38
KDM1A O60341 1/20 0.38
POLB P06746 1/20 0.37
RAB9A P51151 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL316115 0.83 LTA4H (0.42) KMT2AALDH1A1TDP1TSHRMAOA
SCHEMBL1031471 0.82 KMT2A (0.44) MEN1KMT2AAPAF1ALDH1A1TDP1
SCHEMBL8128538 0.82 MAPT (0.38) MEN1KMT2AAPAF1ALDH1A1TDP1
SCHEMBL217907 0.82 RAB9A (0.42) MEN1KMT2AALDH1A1MAOAMAPT
SCHEMBL314481 0.82 KMT2A (0.39) MEN1KMT2AAPAF1ALDH1A1CYP3A4
SCHEMBL8129794 0.82 CLK4 (0.47) MEN1KMT2AALDH1A1TDP1TSHR
SCHEMBL8122786 0.74 LMNA (0.50) ALDH1A1TDP1SMN1; SMN2
SCHEMBL2345370 0.72 MEN1 (1.00) MEN1KMT2AAPAF1ALDH1A1TDP1
SCHEMBL4342200 0.71 MAP4K4 (0.38) KMT2AALDH1A1MAPTHPGD
SCHEMBL15009772 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US claimed
EP-2796456-A1 Bicyclic compounds as Pim inhibitors Amgen Inc. (US) 2014-10-29 EP claimed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US claimed
EP-2649065-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2013-10-16 EP claimed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 WO claimed
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US disclosed
EP-2796456-A1 Bicyclic compounds as Pim inhibitors Amgen Inc. (US) 2014-10-29 EP disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US disclosed
EP-2649065-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2013-10-16 EP disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS PIM1, PIM2, PIM3 MEN1 4135/4885KMT2A 663/4885APAF1 936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.